Metastatic melanoma is the most responsive tumor type for ICT, with about 17% responding to anti-PD-1 antibody, about 27% responding to anti-CTLA-4 antibody, and about 55% responding to their combined therapy (2). Here, CTLA4 is linked to neoplasm.